Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Litigation: Amgen Sues Samsung Bioepis To Enforce 180-Day Notice Requirement

May 01 2019

• By Sue Sutter

Feet partners on black background — Samsung Bioepis opted not to do the 'patent dance' with Amgen over its etanercept biosimilar. • Source: Shutterstock

Related Content

Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit

Apr 29 2019

Biosimilar Labeling Carve-Out Turned Erelzi's Psoriatic Arthritis, Plaque Psoriasis Uses Into 'Another Indication'

Mar 14 2018

US Supreme Court Permits Earlier Biosimilar Launches; Penalty For Declining Patent Dance Uncertain

Jun 13 2017

Related Companies

Amgen, Inc.

Samsung Bioepis Co., Ltd.

Amgen, Inc.

Roche Holding AG

Novartis AG

Novartis AG

Additional Topics

United States Biosimilars Legal Issues Intellectual Property Commercial Inflammation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window